SQUAWK/NEWS
Account
Theme
Account
Menu
Live News CENTRAL_BANK ARTICLE M impact

AbbVie reports 74% response rate for Etentamig in pivotal trial

AbbVie said Etentamig delivered a 74% overall response rate in a pivotal blood-cancer trial, while standard treatments managed 45.7%. Shares were priced at $260.445.

ABBV

AbbVie NYSE:ABBV, the pharmaceutical and biotechnology company, put its cancer pipeline in focus Thursday, with shares priced at $260.445. Etentamig posted a 74% overall response rate in a pivotal blood-cancer trial. Standard treatments achieved 45.7%. The gap was 28.3-perc…

Related stories